Galderma Laboratories LP v. Taro Pharmaceuticals USA Inc
3:15-cv-02814
Overview
Parties
Defendant
Taro Pharmaceuticals USA Inc Operating Company
Represented By
1 Attorneys ListedPatterson & Sheridan LLP
1700 Pacific Avenue, Suite 2650, Dallas, TX 75201
Plaintiff
Galderma Research & Development SNC Operating Company
Represented By
5 Attorneys ListedMunck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
2000 McKinney Avenue, Suite 1900
Munsch Hardt Kopf and Harr
Munsch Hardt Kopf and Harr, 500 N Akard Street
Munck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
2000 McKinney Avenue, Suite 1900, Dallas, TX 75201
Galderma SA NPE (Individual / Inventor)
Represented By
5 Attorneys ListedMunck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
2000 McKinney Avenue, Suite 1900
Munsch Hardt Kopf and Harr
Munsch Hardt Kopf and Harr, 500 N Akard Street
Munck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
2000 McKinney Avenue, Suite 1900, Dallas, TX 75201
Galderma Laboratories LP NPE (Individual / Inventor)
Represented By
5 Attorneys ListedMunck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
2000 McKinney Avenue, Suite 1900
Munsch Hardt Kopf and Harr
Munsch Hardt Kopf and Harr, 500 N Akard Street
Munck Wilson Mandala LLP
12770 Coit Road, Suite 600, Dallas, TX 75251
Munck Wilson Mandala LLP
2000 McKinney Avenue, Suite 1900, Dallas, TX 75201
Court & Judges
Court
District Court, N.D. Texas (txnd)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 10 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇫🇷 France | France Counterpart | View Official Patent → | |
| 🇫🇷 France | France Counterpart | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🌐 PCT International (WIPO) | PCT World Application | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 5 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8071644
Combinations of adapalene and benzoyl peroxide for treating acne lesions
|
Filed: 2009-01-13
Issued: 2011-12-06
|
Active (0.8 yrs remaining)
Expires: 2027-09-04
|
|
|
US8080537
Combinations of adapalene and benzoyl peroxide for treating acne lesions
|
Filed: 2009-05-28
Issued: 2011-12-20
|
Active (0.7 yrs remaining)
Expires: 2027-07-18
|
|
|
US8129362
Combination/association of adapalene and benzoyl peroxide for treating acne lesions
|
Filed: 2007-07-13
Issued: 2012-03-06
|
Active (2.1 yrs remaining)
+548d PTA
Expires: 2029-01-11
|
|
|
US8445543
Combinations of adapalene and benzoyl peroxide for treating acne lesions
|
Filed: 2011-11-30
Issued: 2013-05-21
|
Active (5.0 yrs remaining)
Expires: 2031-11-30
|
|
|
US8809305
Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris
|
Filed: 2009-07-29
Issued: 2014-08-19
|
Active (4.0 yrs remaining)
+488d PTA
Expires: 2030-11-29
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term — No obviousness-type double patenting noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).